Odyssey Therapeutics raises $25M from TPG affiliate in private placement concurrent with IPO at $18/share

In connection with the closing of the IPO, on May 11, 2026, the Company filed an amended and restated certificate of incorporation (the “ Amended and Restated Certificate of Incorporation ”) with the Secretary of State of the State of Delaware. The Company’s board of directors (the “ Board ”) and stockholders previously approved the Amended and Restated Certificate of Incorporation to be effective as of immediately prior to the closing of the IPO.

Effective as of May 11, 2026, the Company adopted amended and restated bylaws (the “ Amended and Restated Bylaws ”) in connection with the closing of the IPO. The Board and stockholders previously approved the Amended and Restated Bylaws to be effective immediately prior to the closing of the IPO.

On May 7, 2026, Odyssey Therapeutics, Inc. (the " Company ") entered into a Share Purchase Agreement (the " Purchase Agreement ") with TPG LSI Rise Orazio II, L.P. (" Purchaser "), an affiliate of an existing stockholder of the Company, for the purchase of an aggregate of 1,388,889 shares (the " Shares ") of the Company’s common stock, par value $0.001 (the " Common Stock "), at a per share price equal to the initial public offering price of $18.00 per share, through a private placement financing (the " Private Placement "), which closed concurrently with the initial public offering of shares of the Company’s Common Stock (the " IPO ").